Načítá se...
Repurposing ribosome-targeting antibiotics to overcome resistance to venetoclax in acute myeloid leukemia
Venetoclax, a selective B-cell lymphoma 2 inhibitor, has shown promise in the treatment of acute myeloid leukemia. However, the development of drug resistance limits its clinical efficacy. In our study, we discovered that ribosome-targeting antibiotics can be repurposed to overcome venetoclax resist...
Uloženo v:
| Vydáno v: | Mol Cell Oncol |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Taylor & Francis
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7051130/ https://ncbi.nlm.nih.gov/pubmed/32158926 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/23723556.2020.1712182 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|